21 years of historical data (2004–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Gyre Therapeutics, Inc. trades at 164.8x earnings, 35% below its 5-year average of 253.5x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 596%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $711M | $1.2B | $1.7B | $602M | $418M | $1.8B | $1.2B | $1.3B | $701M | $114M | $208M |
| Enterprise Value | $701M | $1.2B | $1.7B | $577M | $376M | $1.8B | $1.2B | $1.3B | $691M | $123M | $213M |
| P/E Ratio → | 164.80 | 242.00 | — | 265.00 | — | — | — | — | — | — | — |
| P/S Ratio | 6.72 | 11.70 | 14.91 | 5.88 | 57.00 | 86.66 | — | 221193.86 | 688.14 | 285.46 | 118.83 |
| P/B Ratio | 8.57 | 12.58 | 121.24 | 8.33 | 10.18 | 23.86 | 17.94 | 11.06 | 22.76 | 7.09 | 6.62 |
| P/FCF | — | — | 97.72 | 105.95 | — | — | — | — | — | — | — |
| P/OCF | — | — | 65.32 | 56.36 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Gyre Therapeutics, Inc.'s enterprise value stands at 39.5x EBITDA, 37% below its 5-year average of 62.5x. The Healthcare sector median is 13.8x, placing the stock at a 185% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.61 | 14.62 | 5.64 | 51.28 | 85.29 | — | 215991.70 | 678.92 | 308.36 | 121.48 |
| EV / EBITDA | 39.49 | 69.15 | — | 55.86 | — | — | — | — | — | — | — |
| EV / EBIT | 43.37 | 75.64 | 86.30 | 62.71 | — | — | — | — | — | — | — |
| EV / FCF | — | — | 95.81 | 101.63 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Gyre Therapeutics, Inc. earns an operating margin of 15.3%. Operating margins have expanded from 9.0% to 15.3% over the past 3 years, signaling improving operational efficiency. ROE of 21.5% indicates solid capital efficiency. ROIC of 35.1% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.3% | 96.3% | 95.9% | 95.3% | -4.5% | 56.3% | — | -357800.0% | -1162.0% | -2545.4% | -240.5% |
| Operating Margin | 15.3% | 15.3% | -59.3% | 9.0% | -1141.0% | -273.9% | — | -563700.0% | -2143.6% | -5117.3% | -788.7% |
| Net Profit Margin | 11.4% | 11.4% | -81.9% | 2.3% | -1198.3% | -265.1% | — | -500916.7% | -2118.0% | -4246.9% | -843.5% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 21.5% | 21.5% | -215.7% | 4.1% | -150.1% | -76.9% | -58.6% | -39.9% | -92.1% | -71.4% | -21.0% |
| ROA | 10.0% | 10.0% | -92.3% | 3.3% | -116.8% | -57.4% | -49.4% | -36.6% | -55.6% | -31.5% | -16.3% |
| ROIC | 35.1% | 35.1% | -353.8% | 29.5% | -270.2% | -84.3% | -59.9% | -46.1% | -70.2% | -50.0% | -23.3% |
| ROCE | 16.0% | 16.0% | -79.6% | 16.1% | -141.3% | -78.2% | -60.4% | -44.8% | -93.1% | -85.3% | -19.6% |
Solvency and debt-coverage ratios — lower is generally safer
Gyre Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.1x, which is very conservative (97% below the sector average of 3.1x). The company holds a net cash position — cash of $12M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.03 | 0.01 | 0.06 | 0.02 | 0.03 | — | 0.17 | 1.21 | 1.07 |
| Debt / EBITDA | 0.09 | 0.09 | — | 0.06 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -2.37 | -0.34 | -1.02 | -0.38 | -0.20 | -0.26 | -0.31 | 0.57 | 0.15 |
| Net Debt / EBITDA | -0.58 | -0.58 | — | -2.38 | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -1.91 | -4.33 | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -9.34 |
Net cash position: cash ($12M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
Gyre Therapeutics, Inc.'s current ratio of 3.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.99x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 4.06x to 3.32x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.32 | 3.32 | 2.85 | 4.06 | 3.63 | 5.03 | 3.32 | 25.83 | 4.48 | 1.71 | 1.82 |
| Quick Ratio | 2.99 | 2.99 | 2.64 | 3.56 | 3.63 | 5.03 | 3.32 | 25.83 | 3.87 | 0.82 | 0.92 |
| Cash Ratio | 1.37 | 1.37 | 1.67 | 2.06 | 3.31 | 4.46 | 2.66 | 25.02 | 3.71 | 0.78 | 0.86 |
| Asset Turnover | — | 0.84 | 0.97 | 1.21 | 0.13 | 0.22 | — | 0.00 | 0.03 | 0.01 | 0.03 |
| Inventory Turnover | 0.61 | 0.61 | 1.08 | 0.78 | — | — | — | — | 2.42 | 0.54 | 0.18 |
| Days Sales Outstanding | — | 100.62 | 54.18 | 55.72 | 90.43 | 57.73 | — | — | 8.61 | 28.36 | 102.62 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Gyre Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 0.6% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.6% | 0.4% | — | 0.4% | — | — | — | — | — | — | — |
| FCF Yield | — | — | 1.0% | 0.9% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% |
| Shares Outstanding | — | $102M | $66M | $76M | $31M | $19M | $12M | $11M | $3M | $778780 | $295272 |
Compare GYRE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| GYREYou | $711M | 164.8 | 39.5 | — | 96.3% | 15.3% | 21.5% | 35.1% | 0.1 |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| CANF | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| ABVX | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| RAPT | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| TGTX | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| APGE | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 21 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how GYRE stacks up against sector leader argenx SE.
Start ComparisonGyre Therapeutics, Inc.'s current P/E ratio is 164.8x. This places it at the 50th percentile of its historical range.
Gyre Therapeutics, Inc.'s current EV/EBITDA is 39.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 62.5x.
Gyre Therapeutics, Inc.'s return on equity (ROE) is 21.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -47.8%.
Based on historical data, Gyre Therapeutics, Inc. is trading at a P/E of 164.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Gyre Therapeutics, Inc. has 96.3% gross margin and 15.3% operating margin. Operating margin between 10-20% is typical for established companies.
Gyre Therapeutics, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.